Ruth Gitau
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ruth Gitau has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Barbra A. Richardson
Department of Global Health, University of Washington, Seattle, Washington, United States of America
2 shared publications - Julie Overbaugh
Human Biology Division, Fred Hutchinson Cancer Center
2 shared publications - Linnet N. Masese
Department of Epidemiology
2 shared publications - Susan M. Graham
Department of Global Health, University of Washington, Seattle, USA
2 shared publications - Walter Jaoko
Department of Medical Microbiology and Immunology, University of Nairobi, Nairobi, Kenya
2 shared publications Jeckoniah O Ndinya-Achola
Department of Medical Microbiology, University of Nairobi, Nairobi, Kenya
1 shared publication
Latest Publications
- Open Access
- 3 November 2011
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 11 (1) , 307
A prospective study of vaginal trichomoniasis and HIV-1 shedding in women on antiretroviral therapy
Trichomonas vaginalis has been associated with increased vaginal HIV-1 RNA shedding in antiretroviral therapy (ART)-naïve women. The effect of trichomoniasis on vaginal HIV-1 shedding in ART-treated women has not been characterized. We tested the hypothesis that T. vaginalis infection would increase vaginal HIV-1 RNA shedding in women on ART, and that successful treatment would reduce vaginal HIV-1 RNA levels.
- 3 November 2011
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 11 (1) , 307
Open AccessA prospective study of vaginal trichomoniasis and HIV-1 shedding in women on antiretroviral therapy
Trichomonas vaginalis has been associated with increased vaginal HIV-1 RNA shedding in antiretroviral therapy (ART)-naïve women. The effect of trichomoniasis on vaginal HIV-1 shedding in ART-treated women has not been characterized. We tested the hypothesis that T. vaginalis infection would increase vaginal HIV-1 RNA shedding in women on ART, and that successful treatment would reduce vaginal HIV-1 RNA levels.
- Open Access
- 13 November 2010
- Published by Wolters Kluwer Health in AIDS
- Vol. 24 (17) , 2733-2737
Effect of acquisition and treatment of cervical infections on HIV-1 shedding in women on antiretroviral therapy
Background: Cervicitis increases the quantity of HIV-1 RNA in cervical secretions when women are not taking antiretroviral therapy (ART), and successful treatment of cervicitis reduces HIV-1 shedding in this setting. Objective: To determine the effect of acquisition and treatment of cervical infections on genital HIV-1 shedding in women receiving ART. Design: Prospective cohort study. Methods: We followed 147 women on ART monthly for incident nonspecific cervicitis, gonorrhea, and chlamydia. Cervical swabs for HIV-1 RNA quantitation were collected at every visit. The lower limit for linear quantitation was 100 copies per swab. We compared the prevalence of HIV-1 RNA detection before (baseline) versus during and after treatment of cervical infections. Results: Thirty women contributed a total of 31 successfully treated episodes of nonspecific cervicitis (N = 13), gonorrhea (N = 17), and chlamydia (N = 1). HIV-1 RNA was detected in cervical secretions before, during, and after cervicitis at one (3.2%), five (16.1%), and three (9.7%) visits, respectively. Compared with baseline, detection of HIV-1 RNA was increased when cervical infections were present (adjusted odds ratio 5.7, 95% confidence interval 1.0–30.3, P = 0.04). However, even in the subset of women with cervical HIV-1 RNA levels above the threshold for quantitation, most had low concentrations during cervical infections (median 115, range 100–820 copies per swab). Conclusion: Although these data show a statistically significant increase in cervical HIV-1 RNA detection when cervical infections are present, most cervical HIV-1 RNA concentrations were near the threshold for detection, suggesting that infectivity remains low. Antiretroviral therapy appears to limit increases in genital HIV-1 shedding caused by cervical infections.
- 13 November 2010
- Published by Wolters Kluwer Health in AIDS
- Vol. 24 (17) , 2733-2737
Open AccessEffect of acquisition and treatment of cervical infections on HIV-1 shedding in women on antiretroviral therapy
Background: Cervicitis increases the quantity of HIV-1 RNA in cervical secretions when women are not taking antiretroviral therapy (ART), and successful treatment of cervicitis reduces HIV-1 shedding in this setting. Objective: To determine the effect of acquisition and treatment of cervical infections on genital HIV-1 shedding in women receiving ART. Design: Prospective cohort study. Methods: We followed 147 women on ART monthly for incident nonspecific cervicitis, gonorrhea, and chlamydia. Cervical swabs for HIV-1 RNA quantitation were collected at every visit. The lower limit for linear quantitation was 100 copies per swab. We compared the prevalence of HIV-1 RNA detection before (baseline) versus during and after treatment of cervical infections. Results: Thirty women contributed a total of 31 successfully treated episodes of nonspecific cervicitis (N = 13), gonorrhea (N = 17), and chlamydia (N = 1). HIV-1 RNA was detected in cervical secretions before, during, and after cervicitis at one (3.2%), five (16.1%), and three (9.7%) visits, respectively. Compared with baseline, detection of HIV-1 RNA was increased when cervical infections were present (adjusted odds ratio 5.7, 95% confidence interval 1.0–30.3, P = 0.04). However, even in the subset of women with cervical HIV-1 RNA levels above the threshold for quantitation, most had low concentrations during cervical infections (median 115, range 100–820 copies per swab). Conclusion: Although these data show a statistically significant increase in cervical HIV-1 RNA detection when cervical infections are present, most cervical HIV-1 RNA concentrations were near the threshold for detection, suggesting that infectivity remains low. Antiretroviral therapy appears to limit increases in genital HIV-1 shedding caused by cervical infections.